G. Raggio

Direct Medical Costs of Complications Resulting From Type 2 Diabetes in Hie U.S.

J. O'brien, L. Shomphe, P. Kavanagh, 1998, Diabetes Care.

Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

J. Caro, M. Salas, G. Raggio, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Sumatriptan: Economic Evidence for Its Use in the Treatment of Migraine, the Canadian Comparative Economic Analysis

D. Getsios, G. Raggio, J. Caro, 2001, Cephalalgia : an international journal of headache.

Treatment of Migraine in Canada With Naratriptan: A Cost‐Effectiveness Analysis

D. Getsios, G. Raggio, J. Caro, 2001, Headache.

Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States.

J. Caro, M. Salas, J. O'brien, 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Persistence with treatment for hypertension in actual practice.

J. Caro, M. Salas, G. Raggio, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.

J. Caro, J. O'brien, L. Shomphe, 2000, Clinical therapeutics.

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

Krista F. Huybrechts, J. Caro, K. Huybrechts, 2004, Osteoporosis International.

Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care

J. Caro, D. Getsios, A. Ward, 2001, Neurology.

Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.

J. Caro, J. O'brien, G. Raggio, 2001, PharmacoEconomics.

E1: Compliance as a function of initial choice of antihypertensive drug

J. Caro, M. Salas, G. Raggio, 1997 .